Purpose: So far, only little is known about antidepressant off-label use in pediatric patients. This is the first study examining the prevalence and the risks of off-label antidepressant prescriptions in minors over time in Germany and analyzing patterns regarding age, sex, drug class, and type of off-label use.
| INTRODUCTION
Drugs are frequently prescribed off-label to pediatric patients because agents on the market have often not been studied and approved for this population. 1 This can increase the risk of incorrect dosing and adverse drug events. 2 For antidepressant (AD) compounds, high but varying rates of off-label use (OLU) in pediatric populations have been reported in various countries, including Germany. [3] [4] [5] [6] [7] [8] Antidepressants are prescribed for a variety of indications including depression, sleep disorders, nocturnal enuresis, obsessivecompulsive disorder, anxiety disorders, and chronic pain. Despite the risk of cardiovascular and neurological adverse events, metabolic disorders, and poisoning, 9, 10 and despite worries about an increased risk of suicidal behavior in young patients, 3, 11 increasing pediatric AD use has been observed in several studies from different countries with rates of OLU up to 90.8%. 7, [12] [13] [14] [15] As reported previously, 16 we found a decreasing percentage of off-label prescriptions from 64.2% to 36.3% when examining AD use in minors aged 0 to 17 years in Germany from 2004 to 2011. Another
German study focusing on the medical treatment of adolescents aged 12 to 18 years with a diagnosed depression found a share of off-label AD prescriptions of 45.5% in 2009. 8 However, only very little is known about the risks of AD OLU in pediatric patients. To close this research gap, we use a representative
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sample of minors to investigate the risks of AD OLU compared with the supposedly safer on-label use where the risks of adverse events and the appropriate dosing have been studied in young individuals.
To our knowledge, this is the first study providing detailed analyses of changes in the frequency of OLU over time, stratified by age, sex, and drug class. Further, we are looking at the prescribing doctors 0 specialty and examine, for the first time, whether prescriptions were off-label regarding the age of the patients, the indications that the ADs were prescribed for, or an underlying contraindication.
2 | METHODS
| Data source
We used data from 3 statutory health insurance (SHI) providers that 
| Study design
The study population consisted of minors aged 0 to 17 years, insured in one of the 3 SHIs between 2004 and 2011. The study cohort was ascertained in two steps. First, the share of (off-label) AD prescriptions was examined in cross-sectional analyses for each year. All individuals with continuous insurance coverage either (1) during the whole study year, or (2) from birth in the study year until the end of that year, or (3) from birth in the study year until death in that year, or (4) from start of the study year until death in that year were included.
Second, a cohort including all minors with at least one AD prescription during the study period who were continuously insured for at least 6 months before the prescription (baseline period) and who had no simultaneous on-and off-label prescriptions was defined to investigate the association between AD use and cardiovascular and cerebrovascular events, suicidal events, and death. Cohort entry was defined as the date of the first AD prescription. Patients were followed until the first of the following events: (1) interruption of insurance time for more than 14 days, (2) December 31 of the year in which the subject turned 17, (3) end of the study period, (4) end of insurance including death, and (5) 
| Drug exposure
All ADs (ATC code N06A) were included in the analyses and catego- 
| Covariates
Inpatient and outpatient data were used to identify diagnoses. In addition to all approved indications of the prescribed ADs, the analyses considered other diagnoses of mental and behavioral disorders (ICD-10-GM: F00-F99) and of diseases of the nervous system (G00-G99 • Most off-label prescriptions (29.1% to 43.1%) were offlabel by age.
• Hyperkinetic disorder was the most common diagnosis among pediatric patients with antidepressant prescriptions, which were off-label by indication.
• In 2011, selective serotonin reuptake inhibitors were more frequently prescribed off-label than tricyclic antidepressants (37.7% vs 17.5%).
• Adverse events occurred rarely, and there were no significant differences between on-and off-label use.
quarter of the prescription or in the preceding or following quarter. A prescription was off-label by contraindication if there were diagnoses of contraindications in the quarter of the prescription or if there was a contraindicated medication overlapping the AD prescription. The lowest age limit was used if SPCs of generic preparations gave inconsistent information or if the licensed age varied by indication.
Approved indications and contraindications were assigned to all generic drugs if not all SPCs listed all of them. In the annual crosssectional analyses, the on-/off-label status of each prescription was assessed separately. In the subsequent cohort study, the prescription that led to cohort entry was used to determine whether a patient was an on-or off-label user. As described above, the nested casecontrol study took the timing of the most recent (on-or off-label)
AD use before the event into account. 
| Outcome definition

| Statistical analysis
The prevalence of prescriptions was analyzed stratified by on-label use and OLU, age, sex, and drug class with 95% confidence intervals (CI) calculated using the substitution method. 20 Off-label prescriptions were further analyzed regarding type of OLU, underlying diagnoses, and prescribing doctor 0 s specialty.
In the cohort study, the all-cause mortality rate and the incidence rate (IR) of cardiovascular and cerebrovascular and suicidal events were calculated per 10 000 person-years (py) with corresponding 95% CIs, stratified by on-label and OLU.
We used conditional logistic regression in the nested case-control analysis to obtain confounder-adjusted odds ratios (ORs) with corresponding 95% CIs. The risk of suicidal events associated with current OLU, simultaneous off-and on-label use, recent use, or past use of any AD was compared with current on-label use (reference group). For covariates, a backward selection (Wald test with P < .05
for staying in the model) was performed.
SAS statistical software version 9.3 was used for all analyses.
| Trial registration
The study was registered in the register of studies of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP; No.: EUPAS7034).
3 | RESULTS
| Study population
The Child and adolescent psychiatrists issued 37.6% of the 12 250 AD prescriptions in 2011, followed by doctors for internal and general medicine (21.1%), pediatricians (11.3%), and (adult) psychiatrists (6.7%). The latter had the highest share of off-label prescriptions (Table 1 ). The specialty was unknown/not reported for 11.7%. Doctors with various other fields of specialty prescribed the remaining 11.6%.
| Risks of off-label use
The AD user cohort included 22 294 individuals (at cohort entry 11 630 on-label users, 10 664 off-label users), of whom 43.1% were male ( Table 2 ); 1.6% of the on-label users switched to OLU during their follow-up period (1.9% from off-to on-label use). The share of girls was slightly higher in the group of on-label users (58.7% vs 55.1%).
On-label users were also older (mean age: 14.3 vs 13.4 y). On-and off-label users were similar regarding the prevalence of most comorbidities during the baseline period. Prescriptions of ADs, antiepileptics, antipsychotics, anxiolytics, and psychostimulants during the baseline period occurred at slightly higher rates in the group of off-label users.
In total, we observed 30 subjects with cardiovascular and cerebro- The nested case-control analysis showed no significant differences for the risk of suicidal events between current on-label use and current off-label, current off-and on-label, or recent use of any AD (Table 3) 
| DISCUSSION
Our results showed a high but decreasing share of OLU, a higher prevalence of off-label prescriptions for SSRIs than for TCAs, and a high proportion of prescriptions that were off-label by age. Adverse events were relatively rare, and no significant difference between on-label use and OLU was detected.
AD OLU decreased markedly during the study period. This can be explained by the growing share of SSRI prescriptions, especially fluoxetine. As reported previously, 16 Our analyses showed that AD prescriptions off-label by indication were mostly prescribed to minors with a diagnosis of hyperkinetic disorder. Antidepressants are not licensed for this indication; however, it is known that TCAs are efficacious in its treatment. 21 According to the German guideline, the use of TCAs in pediatric hyperkinetic disorder patients can be indicated, especially if they do not tolerate or respond to treatment with stimulants.
22
Antidepressants were most frequently prescribed by child and adolescent psychiatrists, indicating that many young AD users are treated by doctors specialized in the therapy for mental and behavioral disorders.
The number of subjects suffering from the analyzed adverse events was small, suggesting that these events do not pose a major problem when treating minors with ADs. However, because of the small number of cases, a more detailed analyses stratified by drug class was not possible, and only suicidal events could be analyzed in the nested case-control study. This analysis showed a significantly lower risk of suicidal events for past use compared with current on-label use.
One explanation is that current users of ADs are more likely to currently suffer from depression, the strongest risk factor for suicide. 23 The risk of suicidal events was lower for current OLU compared with current on-label use, although the difference was not statistically significant. This can be explained by the fact that the share of patients with a diagnosed depression was lower in the group of off-label users (22% vs 31%).
Studies from the United States and Canada have shown rates of suicide attempts in young AD users between 24.0 and 29.1 per 1000 py. 24, 25 Comparing results of different studies on suicidality is difficult because of substantial methodological differences. This includes different study populations, medications used by the subjects, and outcome definitions. In our study, suicidal events were identified by inpatient diagnoses only and did not include completed suicide as this information is not available in GePaRD. This and the fact that not all suicidal events are coded by doctors might have led to an underestimation of this end point. 26, 27 Our analysis showed that a prior suicidal event was the strongest predictor for suicidal events. It is known that people with a history of suicidal behavior have a higher risk of suicide. 28 In our study, a history of schizophrenia/delusion, alcohol/drug abuse, and mood disorders, which are also known to increase the risk of suicide in minors, 23 were associated with a higher risk of suicidal events as well. Other known risk factors like social isolation, family history of suicide, abuse, and neglect 23 are not covered by the data in
GePaRD.
There were no striking differences regarding the share of SSRI and TCA prescriptions between suicidal cases with current on-label and those with current OLU. Previous studies similarly did not detect any difference between SSRIs and TCAs and the risk of suicide.
26,29
The size of the used database is a major strength of this study. Our analyses reflect real-world drug use patterns in a population representative for the general population in Germany. 18, 19 Using pharmacy dispensing data to determine drug exposure is considered the gold standard in pharmacoepidemiological research as recall bias cannot occur. 30 Beyond that, it has been shown that drug dispensation data give valid information on drug use in Germany.
19,31
The GePaRD does not contain information on inpatient drug treatment. Accordingly, we were only able to assess outpatient treatment.
Yet because all examined ADs (except hypericum) are available by prescription only, GePaRD should provide valid and almost complete information on outpatient AD use. Because GePaRD contains the exact date of dispensation for prescriptions, the potential for misclassification of drug exposure is low. There is, however, no information on the actually prescribed daily dose and on patients 0 adherence to prescriptions. As approximation, we used the DDD to calculate the time of drug exposure.
As outpatient diagnoses are only related to a quarter of a year in the database, some misclassification is possible regarding underlying diagnoses for prescriptions. For the same reason, it was not possible to use outpatient diagnoses to identify outcomes in the risk analysis, because it would not have been possible to assure that the outcome followed the exposure. This might have contributed to the small number of identified events.
Using claims data for the investigation of suicidality is difficult as suicide-related events are frequently missed or not reported in clinical assessment and are therefore likely to be underestimated. 26, 27 As information about actual suicides is not available in GePaRD, suicidal events in our study do not include completed suicide but only suicidal ideation and intentional self-harm with a suicidal background, making an underestimation of suicidal events even more likely.
Finally, because of the way the cohort for the risk analyses was built, children younger than 6 months were not able to enter the cohort. However, because there were only about 60 children During the 6-month baseline period before the prescription of an antidepressant drug.
younger than one year with AD prescriptions in the cross-sectional studies (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) and because the cohort included more than 22 000 AD users, this should not have affected the results.
| CONCLUSIONS
Despite the decreasing AD OLU in minors during the study period, its extent is still considerable. This does not necessarily indicate inappropriate treatment but rather a lack of clinical trials and subsequently missing approvals in the pediatric population. The low share of ADs prescribed despite the presence of a contraindication and the fact that the risk of adverse events was not higher for off-label than for on-label use support this interpretation.
ETHICS STATEMENT
The Code of Social Law (SGB X) regulates the use of SHI data for scientific research in Germany. The use of the data for this study was approved by all involved SHIs and their governing authorities.
Informed consent and approval by an ethics committee were not required.
